Literature DB >> 22433924

Detection, treatment, and prevention of Clostridium difficile infection.

David L McCollum1, J Martin Rodriguez.   

Abstract

Clostridium difficile is a gram-positive anaerobic bacillus responsible for approximately 1 of 5 cases of antibiotic-associated diarrhea. C difficile infection (CDI) is defined by at least 3 unformed stools in a 24-hour period and stool, endoscopic, or histopathologic test results that indicate the presence of this bacteria. The history of CDI research can be divided into early (before 2000) and modern eras (after 2000). C difficile was first described in 1935, and the characteristics and causes of CDI as well as therapies were identified during the early era of research. During the modern era, CDI has become a more common, aggressive nosocomial infection. Our understanding of the epidemiology, diagnosis, treatment, and prevention of CDI has increased at a rapid pace. We review features of CDI diagnosis, treatment, and prevention.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22433924     DOI: 10.1016/j.cgh.2012.03.008

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  16 in total

Review 1.  Cyclic diguanylate signaling in Gram-positive bacteria.

Authors:  Erin B Purcell; Rita Tamayo
Journal:  FEMS Microbiol Rev       Date:  2016-06-26       Impact factor: 16.408

2.  A Nutrient-Regulated Cyclic Diguanylate Phosphodiesterase Controls Clostridium difficile Biofilm and Toxin Production during Stationary Phase.

Authors:  Erin B Purcell; Robert W McKee; David S Courson; Elizabeth M Garrett; Shonna M McBride; Richard E Cheney; Rita Tamayo
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

3.  MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets.

Authors:  Jennifer Steele; Quanshun Zhang; Gillian Beamer; Michelle Butler; Terry Bowlin; Saul Tzipori
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

Review 4.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 5.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

6.  Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics.

Authors:  Josephine S Kim; Kristy K Ward; Nina R Shah; Cheryl C Saenz; Michael T McHale; Steven C Plaxe
Journal:  Support Care Cancer       Date:  2013-07-10       Impact factor: 3.603

Review 7.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

8.  Regulation of Type IV Pili Contributes to Surface Behaviors of Historical and Epidemic Strains of Clostridium difficile.

Authors:  Erin B Purcell; Robert W McKee; Eric Bordeleau; Vincent Burrus; Rita Tamayo
Journal:  J Bacteriol       Date:  2015-11-23       Impact factor: 3.490

9.  Impact of changes in Clostridium difficile testing practices on stool rejection policies and C. difficile positivity rates across multiple laboratories in the United States.

Authors:  Jessica Cohen; Brandi Limbago; Ghinwa Dumyati; Stacy Holzbauer; Helen Johnston; Rebecca Perlmutter; John Dunn; Joelle Nadle; Carol Lyons; Erin Phipps; Zintars Beldavs; Leigh Ann Clark; Fernanda C Lessa
Journal:  J Clin Microbiol       Date:  2013-11-20       Impact factor: 5.948

10.  Hematologic diseases: high risk of Clostridium difficile associated diarrhea.

Authors:  Tae-Geun Gweon; Myung-Gyu Choi; Myong Ki Baeg; Chul-Hyun Lim; Jae Myung Park; In Seok Lee; Sang Woo Kim; Dong-Gun Lee; Yeon Joon Park; Jong Wook Lee
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.